ljubaphoto Merck (NYSE:MRK) is an American pharmaceutical company whose medications and vaccines play key roles in the fight against viruses, cancer, and cardiovascular diseases. Thesis Over the past two months, Merck's share price has risen more than 17%, reflecting stock market euphoria about the expected Fed interest-rate cuts in 2024, a partnership with Daiichi Sankyo (OTCPK:DSKYF) to develop and subsequently commercialize three experimental antibody-drug conjugates showing promising results in clinical ...

Merck MRK, +0.18% is in talks to buy cancer drugmaker Harpoon Therapeutics HARP, -1.49% for about $700 million, or $23 per share, Bloomberg News reported, citing people familiar with the matter. Merck didn’t comment to Bloomberg, the report said, while Harpoon didn’t respond. Shares of Harpoon closed Friday at $10.55.  ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of pivotal Phase 3 trials for four of its investigational candidates from its diverse pipeline in hematologic malignancies and solid tumors. Global Phase 3 studies have been initiated and are actively enrolling for the following investigational candidates: Bomedemstat, an investigational orally available lysine-specific demethylase 1 (LSD1) inhibitor, being evaluated for t ...

Merck & Co., Inc. (NYSE:MRK) Goldman Sachs Healthcare C-Suite Unscripted Conference January 4, 2024 ET Company Participants Peter Dannenbaum - Head, IR Rob Davis - CEO Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani I suspect that people are going to be strolling in, but I don't like to penalize people who are on time, and let's try to stay on time. So let's get underway here. Welcome to what is by definition, in my opinion, the keynote presentation of this conference. We are th ...

The latest trading session saw Merck (MRK) ending at $114.77, denoting a +1.35% adjustment from its last day's close. The stock outpaced the S&P 500's daily loss of 0.8%. On the other hand, the Dow registered a loss of 0.76%, and the technology-centric Nasdaq decreased by 1.18%.Coming into today, shares of the pharmaceutical company had gained 6.6% in the past month. In that same time, the Medical sector gained 5.8%, while the S&P 500 gained 3.4%.The investment community will be closely monitoring the perfo ...

Sergey Peterman Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 8 years. This is a high frequency breakout subset of the different portfolios types I regularly release has now reached 343 weeks of public selections as part of this ongoing live forward-testing research. Plus, all new long term portfolios for 2024 will be released at the end of December in a Part 2 of this article. 2023 Performance of the MDA Algorithm For 2023, ...

On Dec. 14, Moderna (MRNA -1.93%) and Merck (MRK 0.73%) jointly reported some great news for patients as well as investors: A powerful new cancer therapy is in the works, and the freshly published mid-stage clinical trial data look favorable. Now, the biotech's shares are up by 21% over the last 30 days, and they likely have much further to run over the long term.But the coronavirus vaccine developer's stock actually lost a similar proportion of its value over the last three years, and its revenue is dramat ...

JuSun It’s almost the end of the year, and is a good time to re-evaluate one’s portfolio in terms of potential winners and losers next year. With the market chasing growth stocks to nosebleed valuations, I believe better opportunities can be found to similar moat-worthy enterprises that are trading at far more reasonable valuations with a dividend kicker. This brings me to Merck (NYSE:MRK), which I last covered here in October of last year, noting the expansion of its highly profitable Keytruda drug and ...

A patient and a pharmacist talk to each other. Drazen Zigic/iStock via Getty Images It's been repeated ad nauseam, but there are no guarantees in equity investing. Even the most storied companies are susceptible to fading into the ash heap of history. At the time Lehman Brothers went bankrupt in 2008, it was in business for more than 150 years. The company established itself as the fourth-largest investment bank in the United States. High debt can only be overlooked for so long before the perfect storm brin ...

Fischerrx6 Introduction As we head into the last trading days of 2023, I wanted to cover a stock I haven't discussed before on Seeking Alpha. That company is Merck & Co. (NYSE:MRK), a drug manufacturer with a market cap of more than $270 billion. The reason why I never covered MRK is because I thought it was too boring. I was wrong. Very wrong. Over the past ten years, MRK shares have returned 215%, beating both the healthcare ETF (XLV) and the S&P 500. Data by YCharts Moreover, the stock is yielding 2. ...